system settings, reimbursement, HTA bodies and evaluation, evidence requirements, procurement process, value perception, and key trends and opportunities. This data was gathered through a partnership between Pharmerit and Ethicon Inc. A targeted literature review was conducted to collect information regarding these topics. If gaps in the knowledge were identified after this review, interviews with local affiliates were conducted. Results: Through our methodology and analysis, the following results were identified. Brazil is growing and enjoys the largest economy and most attractive medical device market in Latin America growing 13.6% (CAGR) over the next decade. Health expenditure is valued at US$502 per capita. Brazil has 200 Million people in the public sector, and 51 Million of those also have private insurance. New laws promote the development and purchasing of national products. Both the public and private sectors are regulated by the Ministry of Health (MoH) and ANVISA for premarket regulatory approval. Pricing is negotiated through tenders and purchasing negotiation, and differ by region. At this time Medical Devices do not have price regulation, but in 2015 a working group was created by the MoH in order to evaluate and regulate medical devices' prices. HTA has grown rapidly leading to constrictions in adoption of new technologies and market access. New guidelines were prepared specifically for medical devices (HTA by CONITEC) in order to promote a better evaluation for medical devices.
Objectives: According to GLOBOSCAN 2012 and WHO, 14 .1 million new cancer cases and 8.2 million deaths occurred worldwide in 2012. In Brazil, the incidence of the disease is also increasing as population ages, with 576,000 new cases of cancer expected in 2015. Despite the significant impact of disease and need for monitoring and prevention, epidemiological and economic data that would help decision markers to evaluate unmet needs are still scarce. This study aims to evaluate the epidemiological aspects; economic impact and treatment patterns in a private health insurance plan with approximately 150,000 lives. MethOds: We retrieved data from Evidências-Kantar Health private market administrative claims database from June 2012 to June 2013. After patient de-identification, data on diagnosis, type of drug, and line-of-treatment were collected. All ICDs and treatment patterns were reviewed by an oncologist. Health economist specialists priced the treatments (ex-factory price) in order to assess the budgetary impact. Only oncologic drug costs were considered -antiemetics, corticosteroids and equipment were not included). Exchange rate was 1USD= 3.25BRL. Results: A total of 150 new cases of cancer were retrieved from the database. Median age was 59.5years (3 -89) and body surface 1.775 m2 (0.72 -2.3). The five most prevalent cancers were breast (19%), colon (15%), prostate (11%), nonHodgkin's lymphoma (7%) and lung neoplasm (5%). The budget impact for cancer treatments was USD 1,464,958, (most impacting diseases: USD436,908 for breast, USD428,90 for colorectal and USD177,131 for non-Hodgkin lymphoma). Considering the average cost per patient treated, kidney (USD27,970), colon (USD19,495) and brain cancer (USD17,809) were the most expensive ones. Treatment pattern will be described in details in tables. cOnclusiOns: The increasing incidence of cancer and its costly treatments are significantly affecting the economic sustainability of the healthcare sector. This study maps the most prevalent and costly cancer treatments under a private insurance perspective in Brazil. was done. Results: TLR Avoided probability with DCB was 0,856 vs. 0,600 for PTA. DCB total cost was R$4.468 vs. R$3.737 for PTA. The ICER was R$2.856. In univariate sensitivity the ICER the total DCB cost was tested from -10% to +10%, obtaining ICER values that were from R$2.075 to R$3.637. In the Probabilistic Sensitivity analysis, it was a 24% probability for DCB to be dominant or cost-saving, and 98,3% of been under 3 GDP per Capita for Brazil. cOnclusiOns: DCB showed a 98,3% probability of been cost-effectiveness when compared to PTA and a 24% probability of been cost-saving. Objectives: To analyze how main determinants of competition in six therapeutic target groups -analgesics, tranquilizers, peptic ulcer treatment, cholesterol treatment, benign prostatic hypertrophy and ACE inhibitors-were affected by regulations and drug policies implemented at national level during the last decade in the pharmaceutical market in Argentina. MethOds: The database corresponds to the annual information on retail sales in the Argentine pharmaceutical sector generated by IMS for the period 2005-2012. The estimation strategy takes the form of econometric models of ordinary least squares with year fixed effects and robust standard errors. The dependent variables explain the market shares of each product/ brand per therapeutic class, explained by prices, participant active principles, and a set of variables capturing product differentiation mechanisms implemented by pharmaceutical firms. Each therapeutic class' regression was exposed to a vector of variables capturing the structure of the regulatory framework. Results: In general, prices do not show to be significant determinants of market shares, unlike factors associated with mechanisms of product differentiation do, proving they facilitate the development of brand loyalty and adherence, even with relatively higher prices. On the other hand, the inclusion of new active principles in the Compulsory Health Program (CHP) will act as a boost for priority prescriptions, while the production of generic medicines increases competition, reducing market shares. In addition, the impact of these policies rests heavily on the structure of competition in each therapeutic class. cOnclusiOns: The main health policy recommendations suggest: the need to develop new areas of collaboration with the pharmaceutical sector, enhancing competition in markets with higher levels of concentration, facilitating the evaluation of policies on generic medicines, and successfully regularizing the structure of drugs and products available through the CHP. Objectives: Somatropin is provided in 4 and 12IU presentations by the Brazilian Unified Health System (SUS) for the treatment of Hypopituitarism (HP) and Turner Syndrome (TS). Other presentations are available in the market and are believed to provide a less costly treatment and/or less somatropin waste. MethOds: The registered medicines were obtained from the National Health Surveillance Agency (ANVISA) and their stability from package inserts. Monthly consumption and wastage analysis were estimated using the dose of somatropin for each disease and the average body weight of Minas Gerais State patients. Costs were estimated considering the Maximum Price of Sale to the Government from ANVISA. Results: Seventeen presentations (seven brands) of somatropin are available in the market and those with 28 days stability are not available in SUS. In general, medicines provided by SUS showed higher prices per IU. Immediate-use somatropin (4IU) showed the highest wastage and the highest cost estimates for both diseases. For HP, somatropin wastage of 4 and 12IU presentations was lower than that of the others available in the market. Regarding costs, they emerged in the fifth position of lower average cost for children and in the first and fifth positions for minimum and maximum doses for adults, respectively. For TS, monthly somatropin wastage was of 2.08-2.65IU for 4IU (7-14 days stability), slightly lower than that of 12 to 18IU presentations. Medicines provided by SUS appeared in the ninth position of lower average cost. cOnclusiOns: Medicines incorporated by SUS presented the highest IU prices among registered medicines. Less wastage with incorporated presentations did not translate into better costs results (presentations of 15, 16 and 18IU had lower or similar cost). The purchase of somatropin should be made allowing the participation of presentations of up to 18IU, with 7 to 28 days stability, and considering price per IU.
PRICING AND HEAlTH

PR3
PR4 IMPACT OF MAjOR CHANGES TO THE BRAzIlIAN HEAlTH CARE SySTEM UTIlIzING THE HEAT MAPS PROjECT
Panish JM 1 , Junqueira Junior SM 2 , Cabra HA 3 , Hutzul T 4 , Hensen M 5 1 Ethicon, Somerville, NJ, USA, 2 Johnson & Johnson Medical Brazil, São Paulo, Brazil, 3 Johnson & Johnson Medical, México, D.F., Mexico, 4 Johnson & Johnson Medical Products, Markham, ON, Canada, 5 Pharmerit BV, Rotterdam, The Netherlands Objective: To describe and understand the effects of various changes to the Brazilian Healthcare System, including a new guideline to elaborate HTA studies for Medical Devices, governmental price regulations, and demographics. MethOd: The Heat Maps project provides information from 17 major health care systems around the world, including Brazil. The Heat Maps capture: an overview of the healthcare 1.3% was observed (p< 0.001). For VAS-identified adherent patients, CVR decreased significantly by 4.4% from baseline to 90 days (p< 0.001). However, a significant decrease of 4.3% (p< 0.001) was also observed for VAS-identified non-adherent patients. cOnclusiOns: Patients identified as adherent using the first item of the BAAS showed significantly improved 10-year cardiovascular risk scores after 90 days of treatment with valsartan, compared to patients who were identified as non-adherent. The VAS scale was not sufficiently sensitive to determine the effect of adherence on cardiovascular risk score. Objectives: Patients with Atrial fibrillation (AF), have a five-fold increase in the risk of stroke. Treatment for AF include stroke prevention therapy. Vitamin K antagonists (VKAs) have shown to prevent stroke in AF patients. Apixaban, a novel oral direct factor Xa inhibitor was studied in AF patients whom VKA therapy was unsuitable. Apixaban demonstrated clinical benefit in stroke or systemic embolism reduction without impacting the risk of major bleeding or intracranial hemorrhage. Patient characteristics of the Latin America (LA) cohort and overall population are presented. MethOds: Patients with AF at an increased risk for stroke and whom VKA therapy was unsuitable were randomized to receive apixaban (5 mg twice daily) or aspirin (81 to 324 mg) in a double blind trial. The study recruited from 36 countries from September 2007 through December 2009. Five countries were from LA: Argentina, Brazil, Chile, Colombia, and Mexico. Patient characteristics from the LA cohort, is presented relative to the overall trial population. Results: Of5599 patients in the trial, 1185 were from LA (21.2%). Mean age was similar, 71.5 and 70 for LA and overall cohort respectively. 55% and 58% were males for LA and overall cohort respectively. The LA and overall cohorts had similar rates of prior stroke or TIA, diabetes mellitus and hypertension receiving treatment, at enrollment. Mean CHADS2 score at enrollment was 2,.0 for the apixaban arm and 2.1 for the ASA arm, which is the same for cohorts. Other baseline characteristics were similar. Region subgroup analysis revealed no statistically significant (p> 01.0) interactions between treatment effects and geographic region. cOnclusiOns: Baseline demographic and disease characteristics data from the LA cohort were similar to that of the clinical trial population. Results, in terms of safety and efficacy, given the total population trial, are expected to be consistent since interaction between treatment effects and geography was not significant. Objectives: To examine the initiation of oral antihyperglycemic agents (OAHAs) and/or statins in patients with type 2 diabetes mellitus (T2DM) and assess the time elapsed from diagnosis to treatment initiation and intensification when goals were not achieved in real world practice. MethOds: A retrospective study was performed on 662 medical records of patients with T2DM, diagnosed 24 to 48 months prior to signing the informed consent. The study included thirty-one general practitioner/ specialist sites across Mexico, Argentina and Brazil. Inclusion criteria: age ≥ 21 years at diagnosis; complete record of pre-diagnosis medication and pre-existing CV risk factors and 2 years follow-up records. Exclusion criteria: type 1 diabetes; pregnancy; receiving antihyperglycemic agents or statins prior to diagnosis; initially treated with insulin after T2DM diagnosis; or clinical trial participation during the study period. Descriptive statistics were used for demographic/clinical characteristics. Kaplan-Meier test was used to examine time to treatment and cumulative treatment probability and multivariate logistic regression examined factors associated with such treatment. Results: At diagnosis, patients had a mean age of 53 years; 44% had hypertension, 42% were obese and 23% had hypercholesterolemia. During the 2-year follow-up period, 93% were treated with OAHAs but only 29% of those eligible for statin therapy received statins. Time elapsed before first prescription of OAHA was 59±141 (Mean±SD) and 1 (1, 31) (median [IQR]) days and 230±232 days and 132 (30, 406) days for statin. No variables were associated with OAHA initiation but family history of T2DM and hypercholesterolemia at diagnosis were associated with statin initiation. No antihyperglycemic treatment intensification was recorded in 51%/53% of patients with HbA1c/FPG values above treatment targets during the follow-up period. cOnclusiOns: The delay in treatment of hypercholesterolemia and intensification of treatment for hyperglycemia in patients with T2DM not attaining treatment targets works against effective prevention of chronic complications.
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ARETAEUS: RETROSPECTIvE STUDy OF MEDICATION USAGE PATTERNS FOllOWING THE DIAGNOSIS OF TyPE 2 DIABETES IN lATIN AMERICA
Cv4 ECONOMICS OF DIABETES MEllITUS: THEORy AND EvIDENCE FOR BRAzIlIAN DATA IN 2008
Balbinotto G, Wiest R, Jacinto P Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil intROductiOn: Diabetes Mellitus (DM) is characterized by the high level of blood glucose. Ministry of Health data estimated that Brazil had about 10 million DM cases
BI3
FINANCIAl IMPACT OF HOSPITAl ExPENDITURE IN CHRONIC DISEASES FOR SEGURO POPUlAR
Rodríguez-Aguilar R, Gutiérrez-Delgado C Economic Analysis Unit, Mexico City, Mexico Objectives: Estimate the expenditure in hospital services for cardio-vascular (CVD), malignant tumors (MT) and diabetes financed by Seguro Popular (SP) for 2004-2012 in order to evaluate its midterm financial sustainability. MethOds: Hospital costs for interventions financed by SP for year 2012. Related hospital discharges from the SAEH for 2004-2012. Multiplication of both data generated the cost per ICD-10. The product was then grouped by GBD. Total hospital expenditure for SP, obtained from SINAIS for 2004-2012, was distributed using the cost per GBD. Then the proportion of hospital expenditure related to CVD, MT and diabetes is estimated. Results: Mexico is one of the countries with the highest prevalence of child and adult overweight and obesity (O&O). That situation imposes a great pressure into SP to face an increasing demand of health care for non-communicable chronic diseases (NCD) particularly diabetes, MT and CVD. The average annual hospital expenditure of these groups of diseases represents about USD$273.4 million in 2012 (9.7% of hospital expenditure). Malignant tumors that contributed the most were breast and cervical cancer with 90% of the total expenditure for this group. Acute myocardial infarction represents 66% of total expenditure for cardio-vascular. Under the status quo an increase of 65% in the cost of this group of diseases is expected for 2018. cOnclusiOns: Findings show an increased financial burden for SP generated by the selected NCD. The impact on the public budget that represents this level of hospital expenditure would threaten the sustainability of the SP if current trends hold. Given the demographic transition and level of O&O as risk factors for developing NCD in the coming years it is necessary to strengthen prevention and health promotion to reduce both new cases of NCD and complications in order to decrease their future impact on the SP budget.
BI4 HOSPITAlIzATION COSTS OF TyPE 2 DIABETES MEllITUS (T2DM) PATIENTS IN A PUBlIC HOSPITAl IN BRAzIl
Saad R 1 , Piedade A 2 , Wiens A 1 , Baptista DR 1 , Pontarolo R 1 1 Universidade Federal do Paraná, Curitiba, Brazil, Campinas, Brazil Objectives: Diabetes is considered an outpatient care condition, manageable in the primary care setting, but which complications may lead to hospitalization. There is limited data on the costs of patients hospitalized due to diabetes in Brazil. We aimed to estimate the percentage of type-2 diabetes mellitus (T2DM) patients who were hospitalized and the mean cost per hospitalization within a public hospital in Brazil (SUS). MethOds: T2DM outpatients followed at the Hospital das Clínicas of Universidade Federal do Paraná (HC-UFPR) between 2011 and 2014 were eligible. Data from the last year of treatment were collected and validated within medical charts. We assessed demographics, hospitalization and cause, length and average costs per day of hospitalization. Exchange rate was 1.00USD = 3.21BRL. The study was approved by HC-UFPR IRB. Results: A total of 728 patients with T2DM were evaluated, of which 38 (5.2%, 22 females and 17 males) were hospitalized due to eight different causes. Mean age was 64 years (44 to 84). Main reason for hospitalization was cardiovascular related problems (58.5%), followed by decompensated diabetes treatment (17.0%) and kidney problems (9.4%). Average daily cost ranged from 907BRL (~283USD) (Neurology Center) to 2218BRL (~691USD) (Intensive Cardiology Therapy Center). The amount spent on the Cardiology Center represented 27.5% (188,244BRL) (~58,643USD) of the total, followed by Intensive Cardiology Therapy Center with 18.1% (124,189BRL) (~38,688USD). Total hospital spending with 38 hospitalizations was 685,058BRL (~213,414USD) and mean length of hospitalization was 10 days (1 to 30 days). Mean cost per patient was 18,028BRL (~5,616USD). cOnclusiOns: Hospitalized patients with T2DM represent a significant burden to healthcare payers. However, the amount spent by the hospital is not necessarily the same reimbursed by the Brazilian Public Healthcare System (SUS), which hinders the estimate of the burden for the system as a whole. Objectives: In patients with hypertension, non-adherence to prescribed treatment may contribute to a significant increase in cardiovascular risk. The aims of this study were (1) to examine if two single-item physician-administered adherence scales are predictive of cardiovascular risk and (2) to evaluate whether adherence to antihypertensive medications is associated with at least a one percent reduction in cardiovascular risk over 90 days. MethOds: Pooling data from seven observational studies, this analysis included 8,438 hypertensive patients taking valsartan. A ten-year cardiovascular risk (CVR) score was estimated following the risk scoring system proposed by the SCORE project in Europe. CVR score considered the following variables: age, total cholesterol, current smoking status, systolic blood pressure, and sex. At baseline and 90 days, physicians administered two single-item measures of adherence: the first item of the Basel Assessment of Adherence Scale (BAAS) and the Visual Analogue Scale (VAS). Results: At 90 days, males (4,257) had a significantly higher CVR than females (4,091) (p< 0.001). For BAAS-identified adherent patients, CVR decreased significantly by 2.6% from baseline to 90 days (p-value< 0.001). For BAAS-identified non-adherent patients, a significant but smaller decrease in CVR of
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